| New oral anticoagulants for thromboprophylaxis after total hip or knee arthroplasty. | |
| | |
MedLine Citation:
|
PMID: 20201481 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Patients undergoing total hip or knee arthroplasty are at increased risk of venous thromboembolism (VTE). The long-term sequelae of VTE, such as post-thrombotic syndrome or pulmonary hypertension, can be debilitating with severe morbidity. Conventional anticoagulants have several short-comings: for example, warfarin requires regular coagulation monitoring and low-molecular-weight heparins are inconvenient to use because they require subcutaneous administration. The development of new anticoagulants has focused on 2 classes of compounds: direct thrombin inhibitors and direct factor Xa inhibitors. These new oral agents have shown efficacy in large randomized clinical trials and offer new, more convenient options for anticoagulation. |
| | |
Authors:
|
Richard J Friedman |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Orthopedics Volume: 32 ISSN: 1938-2367 ISO Abbreviation: Orthopedics Publication Date: 2009 Dec |
Date Detail:
|
Created Date: 2010-03-05 Completed Date: 2010-05-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7806107 Medline TA: Orthopedics Country: United States |
Other Details:
|
Languages: eng Pagination: 79-84 Citation Subset: IM |
Copyright Information:
|
Copyright 2009, SLACK Incorporated. |
Affiliation:
|
Department of Orthopaedic Surgery, Roper Hospital, and Department of Orthopaedic Surgery, Medical University of South Carolina, Charleston, South Carolina, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Anticoagulants / therapeutic use* Arthroplasty, Replacement, Hip / adverse effects*, methods Arthroplasty, Replacement, Knee / adverse effects*, methods Drug Design* Factor Xa / antagonists & inhibitors Humans Postoperative Complications / etiology, prevention & control* Primary Prevention Pulmonary Embolism / etiology, prevention & control Randomized Controlled Trials as Topic Thrombin / antagonists & inhibitors Venous Thrombosis / etiology, prevention & control* |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; EC 3.4.21.5/Thrombin; EC 3.4.21.6/Factor Xa |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparison of ACCP and AAOS guidelines for VTE prophylaxis after total hip and total knee arthroplas...
Next Document: Nitric oxide, oxygen, and superoxide formation and consumption in macrophages and colonic epithelial...